MCK - McKesson Corporation

NYSE - Nasdaq Real Time Price. Currency in USD
130.53
+0.06 (+0.05%)
As of 1:05PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close130.47
Open130.77
Bid130.68 x 800
Ask130.85 x 800
Day's Range129.22 - 131.27
52 Week Range117.19 - 178.86
Volume551,106
Avg. Volume1,542,053
Market Cap25.502B
Beta (3Y Monthly)1.55
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.56 (1.19%)
Ex-Dividend Date2018-11-30
1y Target EstN/A
Trade prices are not sourced from all markets
  • Will the Bay Area quietly lose another Fortune 500 headquarters to Texas?
    American City Business Journals5 days ago

    Will the Bay Area quietly lose another Fortune 500 headquarters to Texas?

    San Francisco quietly lost the headquarters of Core-Mark Holding Co., which disclosed on an earnings call that it's moving its headquarters to Dallas next year. Will this health care company follow?

  • Thomson Reuters StreetEvents6 days ago

    Edited Transcript of MCK earnings conference call or presentation 25-Oct-18 12:00pm GMT

    Q2 2019 McKesson Corp Earnings Call

  • The Wall Street Journal12 days ago

    [$$] Longtime McKesson CEO to Step Down

    will retire next year, capping a 17-year reign in which he helped build one of the country’s largest pharmaceutical wholesalers despite weathering shareholder criticism over his compensation and handling of the opioid crisis. , McKesson’s lead independent director, will take over as chairman of the board, the company said Thursday. “This is the right time to turn the leadership reins over to the next generation and no one is better equipped than Brian to lead McKesson into the future,” Mr. Hammergren said in a written statement.

  • Morningstar13 days ago

    McKesson Is Deeply Discounted

    Despite the tumult that has engulfed its operating environment, we believe  McKesson MCK will remain a key healthcare player and be able to produce outsize economic value. Its fiscal second quarter reflected a stabilization of near-term issues as the company reported earnings above consensus and raised the lower end of its full-year earnings per share guidance. After factoring in these latest results, we are reiterating our $210 fair value estimate and wide economic moat rating for the pharmaceutical distributor.

  • Simply Wall St.18 days ago

    Should You Worry About McKesson Corporation’s (NYSE:MCK) CEO Pay?

    John Hammergren has been the CEO of McKesson Corporation (NYSE:MCK) since 2001. First, this article will compare CEO compensation with compensation at other large companies. After that, we will consider Read More...

  • McKesson Corp (MCK) Q2 2019 Earnings Conference Call Transcript
    Motley Fool19 days ago

    McKesson Corp (MCK) Q2 2019 Earnings Conference Call Transcript

    MCK earnings call for the period ending September 30, 2018.

  • International Headwinds Keep Hammering McKesson
    Motley Fool19 days ago

    International Headwinds Keep Hammering McKesson

    The drug distributor's foreign exposure remains a challenge.

  • McKesson (MCK) Beats Q2 Earnings, Misses Revenue Estimates
    Zacks19 days ago

    McKesson (MCK) Beats Q2 Earnings, Misses Revenue Estimates

    McKesson's (MCK) Q2 results benefit from solid performance in the Medical-Surgical Solutions segment.

  • McKesson (MCK) Surpasses Q2 Earnings Estimates
    Zacks19 days ago

    McKesson (MCK) Surpasses Q2 Earnings Estimates

    McKesson (MCK) delivered earnings and revenue surprises of 9.76% and -0.90%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press19 days ago

    McKesson: Fiscal 2Q Earnings Snapshot

    On a per-share basis, the San Francisco-based company said it had profit of $2.51. Earnings, adjusted for one-time gains and costs, were $3.60 per share. The results exceeded Wall Street expectations. ...

  • Benzinga20 days ago

    McKesson's Q2 Earnings Preview

    McKesson (NYSE: MCK ) unveils its next round of earnings this Thursday, Oct. 25. Here is Benzinga's everything-that-matters guide for the Q2 earnings announcement Earnings and Revenue Analysts expect McKesson ...

  • Medical Product Earnings Lineup for Oct 25: SYK, CERN & More
    Zacks20 days ago

    Medical Product Earnings Lineup for Oct 25: SYK, CERN & More

    Long-term potential of the Medical Products industry looks promising at the moment amid certain short-term geopolitical insecurities.

  • Will Core Business Units Aid McKesson's (MCK) Q2 Earnings?
    Zacks25 days ago

    Will Core Business Units Aid McKesson's (MCK) Q2 Earnings?

    McKesson (MCK) is expected to gain from strong segmental performances in Q2 of fiscal 2019.

  • Remembering Microsoft co-founder Paul Allen, dead at 65
    Yahoo Finance28 days ago

    Remembering Microsoft co-founder Paul Allen, dead at 65

    Yahoo Finance's LIVE market coverage and analysis of what you need to watch in the stock market begins each day at 9:00 a.m. ET.

  • Salesforce vs. Twitter in San Francisco homeless tax fight
    Associated Press29 days ago

    Salesforce vs. Twitter in San Francisco homeless tax fight

    SAN FRANCISCO (AP) — San Francisco has come to be known around the world as a place for aggressive panhandling, open-air drug use and sprawling tent camps, the dirt and despair all the more remarkable for the city's immense wealth.

  • Analyzing Gilead Sciences’ Research Pipeline Developments
    Market Realistlast month

    Analyzing Gilead Sciences’ Research Pipeline Developments

    On October 3, Gilead Sciences (GILD) reported the results from a phase three study evaluating the safety and efficacy of Biktarvy for treating HIV-1 infections in treatment-naive patients. The drug was found to be statistically non-inferior to a regimen of abacavir, dolutegravir, and lamivudine through 96 weeks of therapy.

  • Reuterslast month

    McKesson's Change Healthcare hires IPO underwriters -sources

    Change Healthcare LLC, a healthcare technology company majority-owned by U.S. drug wholesaler McKesson Corp, has hired underwriters for an initial public offering that could value it at as much as $12 billion, including debt, people familiar with the matter said on Wednesday. The move comes after McKesson Chief Executive John Hammergren said in January that he intended to take Change Healthcare public. Tapping underwriters shows that McKesson is gearing up for the IPO, which the sources said is expected to take place in the first half of 2019.

  • Morningstar2 months ago

    Healthcare: Valuations Improve as Concerns Over Drug Pricing Pressures Begin to Abate

    Overall, healthcare valuations have slightly risen to a price/fair value of 1.07, up from 0.98 at the end of the second quarter and 1.04 at the start of the year, but the differences in industry valuations continue to suggest drug, biotech, and drug supply chain industries are the most undervalued areas. Innovative new drug launches combined with strong advancements in drug pipelines are supporting a steady growth outlook for the drug and biotech industries. Concerns around U.S. governmental reforms addressing drug pricing appear to be easing on the valuations for drug manufacturers with the majority of reform concerns still surrounding potential changes to the drug supply chain.

  • Analyzing Henry Schein’s Valuation Trend
    Market Realist2 months ago

    Analyzing Henry Schein’s Valuation Trend

    Henry Schein (HSIC) generated revenues of $3.33 billion in the second quarter, compared to revenues of $3.06 billion in the second quarter of 2017. For fiscal 2018 and 2019, the company is expected to generate revenues of $13.41 billion and $14.05 billion, respectively, compared with revenues of $12.46 billion in fiscal 2017.

  • McKesson Corporation (NYSE:MCK): Time For A Financial Health Check
    Simply Wall St.2 months ago

    McKesson Corporation (NYSE:MCK): Time For A Financial Health Check

    Investors pursuing a solid, dependable stock investment can often be led to McKesson Corporation (NYSE:MCK), a large-cap worth US$26.33b. Market participants who are conscious of risk tend to search forRead More...

  • Drug commercials you see on TV may be overhauled
    Yahoo Finance Video28 days ago

    Drug commercials you see on TV may be overhauled

    Pharmaceutical companies could soon be required to include the list price of medicines in their TV ads. Yahoo Finance’s Alexis Christoforous and Sibile Marcellus discuss the details.